The mode of action of combined GARP:TGF-β1/PD-1 blockade in MC38 tumors contrasts with that previously described in CT26 tumors, in which it increased effector functions of already present anti-tumor CD8 T cells, without increasing T cell infiltration or blood vessel density. This evidence concerns the gene TGFB1 and neoplasm.